Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase
about
HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignMolecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine TriphosphateAnalysis of Ribonucleotide 5’ -Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-dependent RNA Polymerase Using Non-Radioactive Polymerase AssaysBiochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication.Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C VirusSimple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5'-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase.Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.Nucleosides for the treatment of respiratory RNA virus infections.
P2860
Q26782405-40215E30-C1AC-4666-A677-ED952AFE53A0Q28071809-C656A8F9-25BC-4C5E-861A-A9A5980914F1Q28548547-036B4B1D-6DFB-4E03-8E9D-AF8B202DF000Q28581011-590B3C3F-FFA6-45DB-B5B4-757ED03BC580Q38833628-70AA7427-661D-4E52-B36D-458509501F62Q38976791-D29A1E25-8C95-4AFE-B8D3-E2FF963DE2ADQ40046618-C89B0C37-3A3E-4687-AE12-3C04730985BAQ40719246-087E3846-E501-4752-B8FA-92C6D02A70C8Q49185722-32FE8D4F-4DEA-463D-883B-542FAA1E581EQ52326653-BCBE06DF-AED8-4D8C-B67C-5133C9CB6233Q52644426-DB3EAD41-6EDD-4F39-A1DC-BCE246AE2CD1
P2860
Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@ast
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@en
type
label
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@ast
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@en
prefLabel
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@ast
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@en
P2093
P2860
P356
P1476
Efficiency of incorporation an ...... t hepatitis C virus polymerase
@en
P2093
Guangyi Wang
Jerome Deval
Leo Beigelman
Natalia Dyatkina
Zhinan Jin
P2860
P304
P356
10.1128/AAC.02666-14
P407
P577
2014-04-14T00:00:00Z